Global prevalence of neuropathic pain is 6.9–10%. Drug treatments have limited efficacy for many people, but PNS is a promising alternative with minimal side effects.
Excessive intestinal barrier permeability is increasingly being diagnosed, but what do we know about the causes and potential health consequences? Can intestinal barrier damage be prevented or repaired?
The causal effect of cancer and cancer therapies on the development of heart failure is well known, but what about the other way around? Explore the evidence for the pathophysiological pathways linking tumor growth with heart failure.
LADA shares features with type 1 and 2 diabetes, but deeper understanding of the disease is vital. Discover what’s known about its pathogenesis, clinical features, diagnosis, prognosis, and treatment.
Two-hour post-load glucose is better at detecting dysglycemia and predicting cardiovascular events than HbA1c in patients with coronary artery disease.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Genetic testing was needed to diagnose the mitochondrial disorder MIDD in a woman with diabetes, weight loss, and poor glycemic control. Glycated hemoglobin and pancreatic function improved after treatment with a DPP-4 inhibitor.
A rare case of fulminant type 1 diabetes induced by SJS/TEN, which had developed in a patient taking carbamazepine and phenytoin. Glucose monitoring should be considered for patients with SJS/TEN.
The GLP-1 receptor agonist dulaglutide was unintentionally used by a woman with type 2 diabetes until the third trimester of an unplanned and unrecognized pregnancy, but what was the outcome?
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
The homeo-fit-prolactin hypothesis proposes a causal metabolic role for prolactin with hypoprolactinemia and hyperprolactinemia leading to adverse metabolic alterations. However, prolactin within the normal range and up to four times the upper …
The worldwide prevalence of diabetes continues to rise, with projections indicating that there will be ~783.2 million individuals aged 20–79 affected by the condition by 2045 [ 1 ]. Type 2 diabetes comprises around 90% of all cases and exerts a …
The prevalence of type-2 diabetes mellitus (T2DM) has increased over 10-fold in the past 40 years in China, which now has the largest T2DM population in the world. Insulin resistance and β-cell dysfunction are the typical features of T2DM.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
Type 1 diabetes is a lifelong disease requiring intensive insulin treatment and daily monitoring of blood glucose levels. Despite efforts to maintain the glucose levels as close as possible to the recommended target, the majority of patients do …
Acute myocardial infarction (AMI) is the leading cause of mortality globally [ 1 ], with the incidence of non-ST segment myocardial infarction (NSTEMI), in particular, increasing [ 2 ]. Diabetes mellitus is an important risk factor for NSTEMI, with …
Type 1 diabetes is a life-long chronic autoimmune disease with an annual incidence among young people (under 20 years) of around 130,000 worldwide [ 1 ]. Its development typically runs from seroconversion (stage 1) to hyperglycaemia (stage 2), to …
Managing Inherited Metabolic Disorders (IMDs) at risk for hypoglycemia, such as Glycogen Storage Diseases (GSDs), Hereditary Fructose Metabolism Disorders (HFMDs) and Congenital Hyperinsulinism (CH), poses challenges in dietary treatments and …
Excessive intestinal barrier permeability is increasingly being diagnosed, but what do we know about the causes and potential health consequences? Can intestinal barrier damage be prevented or repaired?
LADA shares features with type 1 and 2 diabetes, but deeper understanding of the disease is vital. Discover what’s known about its pathogenesis, clinical features, diagnosis, prognosis, and treatment.
Global prevalence of neuropathic pain is 6.9–10%. Drug treatments have limited efficacy for many people, but PNS is a promising alternative with minimal side effects.
Once weekly insulin efsitora alfa reduces HbA1c by a similar amount to daily insulin degludec in people with type 2 diabetes, results of the QWINT-2 trial show.
